| Revenue growth | Like-for-like Q2 revenue up ~20% YoY; reported figures distorted by one-offs. |
|---|---|
| Margins | Ex-IGI EBITDA 21%; adjusted PAT margin 11.4%; H2 improvement guided. |
| Demand visibility | India outgrew IPM: 16.7% vs 13.8%; EM secondary sales strong. |
| Management confidence | Over-optimistic; H2 recovery asserted, not yet evidenced. |
Growth
Like-for-like revenue ~20% in Q2, ~18% in H1; NA core +31%, EM +33%, Europe only +6.2%.
Outlook
Gross debt to zero by end-FY27; H2 cash generation ₹700-800 Cr; net cash ~₹1,200 Cr targeted; EM growth 15-20% p.a.
Risks
Negative H1 operating cash; gross debt ₹867 Cr; litigation settlements continuing; weak European generics; H2 cash recovery unproven.
Earnings Call Transcript filed with NSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,590.00
- Market cap
- ₹73,096 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 50.4×Sector 42.0×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).